Literature DB >> 17851803

Completeness of registration of oral clefts in a medical birth registry: a population-based study.

Christer Kubon1, Ase Sivertsen, Hallvard Andreas Vindenes, Frank Abyholm, Allen Wilcox, Rolv Terje Lie.   

Abstract

BACKGROUND: Epidemiological surveillance and research on birth defects require accurate diagnosis and adequate registration. In this regard, the performance of national birth registries is not well described.
METHODS: We linked clinical data from all 3,616 cleft cases treated in Norway between 1967 and 1998 with data from the Medical Birth Registry of Norway, and calculated the proportion of clinically verified cases reported to the Registry, stratified by severity.
RESULTS: The cleft type most completely ascertained was cleft lip and palate (CLP), of which 94% were reported. Ascertainment was less complete for cleft lip alone (83% recorded), and cleft palate only (CPO) (57% recorded). For each of the three types of clefts, completeness of reporting depended on severity of the cleft. For example, 71% of cases with severe CPO were reported, while only 11% of cases with mild CPO were reported.
CONCLUSIONS: Ascertainment was strongly related to cleft type and severity. To the degree that severity of birth defects may be related to their cause, these patterns of registration have implications for surveillance of birth defects as well as the conduct of etiologic studies. The large proportion of cleft palate cases unrecorded at birth suggests that clinical examination of the newborn palate is often inadequate.

Entities:  

Mesh:

Year:  2007        PMID: 17851803     DOI: 10.1080/08037050701645090

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  14 in total

1.  Familial risks of oral clefts.

Authors:  Melissa Lees
Journal:  BMJ       Date:  2008-02-04

2.  First-trimester nonsystemic corticosteroid use and the risk of oral clefts in Norway.

Authors:  Hildur Skuladottir; Allen Wilcox; Robert McConnaughey; Hallvard Vindenes; Rolv T Lie
Journal:  Ann Epidemiol       Date:  2014-07-08       Impact factor: 3.797

3.  Safety of ginger use in pregnancy: results from a large population-based cohort study.

Authors:  Kristine Heitmann; Hedvig Nordeng; Lone Holst
Journal:  Eur J Clin Pharmacol       Date:  2012-06-17       Impact factor: 2.953

4.  Triptan safety during pregnancy: a Norwegian population registry study.

Authors:  Kateřina Nezvalová-Henriksen; Olav Spigset; Hedvig Nordeng
Journal:  Eur J Epidemiol       Date:  2013-07-25       Impact factor: 8.082

5.  Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway.

Authors:  Maria Romøren; Morten Lindbæk; Hedvig Nordeng
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

6.  Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study.

Authors:  K Nezvalová-Henriksen; O Spigset; H Nordeng
Journal:  BJOG       Date:  2013-03-14       Impact factor: 6.531

7.  Excess risk of adverse pregnancy outcomes in women with porphyria: a population-based cohort study.

Authors:  Mette Christophersen Tollånes; Aasne Karine Aarsand; Sverre Sandberg
Journal:  J Inherit Metab Dis       Date:  2010-10-27       Impact factor: 4.982

8.  Exposure to non-steroidal anti-inflammatory drugs during pregnancy and the risk of selected birth defects: a prospective cohort study.

Authors:  Marleen M H J van Gelder; Nel Roeleveld; Hedvig Nordeng
Journal:  PLoS One       Date:  2011-07-18       Impact factor: 3.240

9.  Effects of codeine on pregnancy outcome: results from a large population-based cohort study.

Authors:  Kateřina Nezvalová-Henriksen; Olav Spigset; Hedvig Nordeng
Journal:  Eur J Clin Pharmacol       Date:  2011-06-09       Impact factor: 2.953

10.  Pregnancy outcome after use of cranberry in pregnancy--the Norwegian Mother and Child Cohort Study.

Authors:  Kristine Heitmann; Hedvig Nordeng; Lone Holst
Journal:  BMC Complement Altern Med       Date:  2013-12-07       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.